Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: AZD-3199; Formoterol Fumarate

Criteria

Inclusion Criteria:

• COPD

• Current or exsmokers, 10 pack years

Exclusion Criteria:

• Asthma

• Any clinically relevant abnormal findings at screening examinations

• Recent COPD exacerbation